Yamagami Wataru, Aoki Daisuke
Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan.
J Obstet Gynaecol Res. 2015 Dec;41(12):1861-9. doi: 10.1111/jog.12833. Epub 2015 Sep 30.
The Japan Society of Obstetrics and Gynecology collects and analyzes annual data on gynecologic cancers from member institutions. Here we present the Treatment Annual Report for 2007. Data on the prognosis of 3381 patients with cervical cancer, 3681 with endometrial cancer, and 2367 with ovarian cancer for whom treatment was initiated in 2007 were analyzed in the Treatment Annual Report. In the 2007 Treatment Annual Report, stage I accounted for 53.1%, stage II for 24.4%, stage III for 14.2%, and stage IV for 8.3% of all patients with cervical cancer. Stage I accounted for 64.8%, stage II for 8.2%, stage III for 20.2%, and stage IV for 6.9% of all patients with endometrial cancer. Stage I accounted for 41.4%, stage II for 9.9%, stage III for 30.6%, and stage IV for 8.6% of all patients with ovarian cancer. The 5-year overall survival rates for patients with cervical cancer were 91.8% for stage I, 71.5% for stage II, 53.0% for stage III, and 23.7% for stage IV; those for patients with endometrial cancer were 95.3%, 89.8%, 75.6%, and 29.1%, and those for patients with ovarian surface epithelial-stromal tumors were 91.5%, 76.1%, 46.9%, and 31.3%, respectively.
日本妇产科学会收集并分析了会员机构提供的妇科癌症年度数据。在此，我们呈现2007年治疗年度报告。该报告分析了2007年开始接受治疗的3381例宫颈癌患者、3681例子宫内膜癌患者和2367例卵巢癌患者的预后数据。在2007年治疗年度报告中，宫颈癌患者中I期占所有患者的53.1%，II期占24.4%，III期占14.2%，IV期占8.3%。子宫内膜癌患者中I期占所有患者的64.8%，II期占8.2%，III期占20.2%，IV期占6.9%。卵巢癌患者中I期占所有患者的41.4%，II期占9.9%，III期占30.6%，IV期占8.6%。宫颈癌患者I期的5年总生存率为91.8%，II期为71.5%，III期为53.0%，IV期为23.7%；子宫内膜癌患者的5年总生存率分别为95.3%、89.8%、75.6%和29.1%，卵巢表面上皮-间质肿瘤患者的5年总生存率分别为91.5%、76.1%、46.9%和31.3%。
